Every 8-K that ENSYSCE BIOSCIENCE WTS (ENSCW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ENSCW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENSCW filings page.
Ensysce Biosciences Inc. has received a Nasdaq notice that it no longer meets the exchange’s minimum $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026. The company must submit a compliance plan within 45 days, by July 6, 2026.
If Nasdaq accepts the plan, Ensysce could receive up to 180 days from May 21, 2026 to regain compliance. The company plans to submit a plan and explore options, but there is no assurance Nasdaq or a Nasdaq Hearings Panel will ultimately permit continued listing.
Ensysce Biosciences reported first quarter 2026 results and outlined key pipeline and strategic developments. Federal grant revenue was $960,999, while research and development expenses rose to $3,346,881 and general and administrative expenses were $1,176,348. Net loss attributable to common stockholders widened to $3,556,415, or $(0.52) per share.
Cash and cash equivalents fell to $745,482 as of March 31, 2026, contributing to a stockholders’ equity deficit of $(669,012). Operationally, the company reached 50% of the interim enrollment target in its pivotal PF614-301 Phase 3 pain trial, advanced its PF614-MPAR® overdose-protected opioid program with new clinical data and IRB approval for PF614-MPAR-102 Part 3, and expanded its ADHD and OUD pipelines and patent estate. The board also launched a formal review of strategic alternatives, including potential partnerships and licensing deals.
Ensysce Biosciences reported fourth quarter and full year 2025 results alongside clinical and regulatory progress for its opioid safety pipeline. The company advanced lead pain candidate PF614 into a pivotal Phase 3 post‑surgical pain trial and continued development of PF614‑MPAR, which has FDA Breakthrough Therapy designation for its overdose‑protection technology.
PF614‑301 Phase 3 enrollment is underway, and the FDA provided supportive feedback for PF614‑MPAR, including potential use of a streamlined 505(b)(2) pathway and overdose‑protection labeling. Ensysce also expanded its intellectual property, with a new U.S. patent on MPAR® technology extending protection to 2042 and a European notice of allowance for an amphetamine prodrug patent.
Financially, federal grant funding was $5.1 million in 2025, while research and development expenses rose to $10.4 million and general and administrative costs were $4.9 million. Net loss attributable to common stockholders increased to $10.2 million for 2025, with fourth quarter loss of $2.8 million. Cash and cash equivalents were $4.3 million at December 31, 2025, supported by $8.7 million of net cash provided by financing activities. As a clinical‑stage biotech, the company expects continued losses as it invests in late‑stage trials and pipeline growth.
Ensysce Biosciences, Inc. filed a Certificate of Correction with the State of Delaware on March 18, 2026 to fix a scrivener’s error in its Certificate of Designation for Series B Preferred Stock, which is part of its Certificate of Incorporation. The full correction text is provided in Exhibit 3.1.
Ensysce Biosciences received a Nasdaq notice that its common stock no longer meets the exchange’s minimum bid price requirement, because the share price has closed below $1.00 for 30 consecutive business days. This puts the company at risk of eventually losing its Nasdaq listing.
The company has 180 calendar days, until August 24, 2026, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. The notice does not immediately affect trading, and the shares continue to trade on the Nasdaq Capital Market under the symbol ENSC while the company monitors its bid price and evaluates options.